Exploring how Salmonella bacteria can be disrupted to prevent infections
Official title: Using Salmonella Pathogenesis and Cell Biology as a Discovery Tool
Funded at University of Colorado · NIH-10795916 · Data updated 2026-11-12
This study is looking for new ways to fight harmful bacteria like Salmonella by finding tiny molecules that can break down their protective membranes without hurting our own cells, with a special focus on a promising compound called D66.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project start | March 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $195,625 |
| NIH project number | 5R21AI171945-02 |
| Project ID | NIH-10795916 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by Gram-negative bacteria, such as Salmonella.
✕Less likely to help
Patients with infections caused by Gram-positive bacteria or those who do not have bacterial infections may not benefit from this research.
What this research studies
This research investigates the inner membranes of pathogenic Gram-negative bacteria, like Salmonella, to identify small molecules that can interrupt their ability to cause disease. By using a method called SAFIRE, the study aims to find compounds that can damage bacterial membranes without harming human cells. The focus is on a specific compound, D66, which has shown promise in disrupting bacterial membranes while preserving the integrity of host cells. This approach could lead to new treatments for bacterial infections by targeting the bacteria's defenses.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively combat bacterial infections with minimal side effects for patients.
How similar studies have gone: Other research has shown success in targeting bacterial membranes with small molecules, indicating that this approach has potential for effective treatment.
Where this research is happening
-
University of Colorado
Boulder, United States Active
Researchers
- Principal investigator: Detweiler, Corrella S — University of Colorado
- Study coordinator: Detweiler, Corrella S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.